Geode Capital Management LLC Raises Holdings in Evolus, Inc. (NASDAQ:EOLS)

Geode Capital Management LLC increased its stake in Evolus, Inc. (NASDAQ:EOLS) by 0.3% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,214,590 shares of the company’s stock after purchasing an additional 3,969 shares during the period. Geode Capital Management LLC owned 1.92% of Evolus worth $13,412,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Barclays PLC raised its stake in shares of Evolus by 268.0% during the 3rd quarter. Barclays PLC now owns 93,662 shares of the company’s stock valued at $1,518,000 after buying an additional 68,213 shares during the last quarter. Principal Financial Group Inc. boosted its position in Evolus by 9.8% in the 4th quarter. Principal Financial Group Inc. now owns 33,370 shares of the company’s stock worth $368,000 after purchasing an additional 2,989 shares in the last quarter. Lord Abbett & CO. LLC grew its stake in shares of Evolus by 23.4% during the 3rd quarter. Lord Abbett & CO. LLC now owns 995,449 shares of the company’s stock worth $16,126,000 after purchasing an additional 188,685 shares during the period. Jane Street Group LLC increased its holdings in shares of Evolus by 47.0% during the 3rd quarter. Jane Street Group LLC now owns 91,899 shares of the company’s stock valued at $1,489,000 after purchasing an additional 29,396 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its position in Evolus by 63.5% during the third quarter. JPMorgan Chase & Co. now owns 169,926 shares of the company’s stock valued at $2,753,000 after buying an additional 65,972 shares during the period. 90.69% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Evolus

In other Evolus news, CFO Sandra Beaver sold 8,996 shares of the business’s stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $13.26, for a total value of $119,286.96. Following the transaction, the chief financial officer now directly owns 173,583 shares in the company, valued at $2,301,710.58. The trade was a 4.93 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Rui Avelar sold 27,904 shares of Evolus stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $13.26, for a total transaction of $370,007.04. Following the sale, the insider now directly owns 362,467 shares in the company, valued at approximately $4,806,312.42. The trade was a 7.15 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 60,575 shares of company stock worth $794,369. Insiders own 6.10% of the company’s stock.

Evolus Stock Performance

NASDAQ:EOLS opened at $10.38 on Tuesday. The company has a market cap of $660.03 million, a P/E ratio of -11.41 and a beta of 0.97. Evolus, Inc. has a twelve month low of $8.67 and a twelve month high of $17.82. The company’s 50-day moving average price is $12.54 and its 200-day moving average price is $13.05. The company has a current ratio of 2.47, a quick ratio of 2.23 and a debt-to-equity ratio of 20.58.

Wall Street Analyst Weigh In

EOLS has been the topic of a number of analyst reports. Needham & Company LLC restated a “buy” rating and set a $22.00 target price on shares of Evolus in a research report on Wednesday, April 9th. Barclays upped their target price on Evolus from $22.00 to $25.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 5th. HC Wainwright reaffirmed a “buy” rating and set a $27.00 price objective on shares of Evolus in a report on Thursday, April 10th. Finally, BTIG Research initiated coverage on shares of Evolus in a research note on Thursday, April 17th. They issued a “buy” rating and a $21.00 price target on the stock. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, Evolus presently has an average rating of “Buy” and an average price target of $23.75.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.